CP and neoplasm: Furthermore, in vivo results showed that combining CP@NP‐cRGD with AZD9291 significantly decreased the growth of NSCLC AZD9291 resistance‐tumor xenografts and exhibited excellent targeting properties, sustained releasing potential, good stability, and low toxicity.